ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has form...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Expert Rev Anticancer Ther
Autori principali: Fizazi, Karim, Albiges, Laurence, Loriot, Yohann, Massard, Christophe
Natura: Artigo
Lingua:Inglês
Pubblicazione: Informa Healthcare 2015
Soggetti:
Drug Profile
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673554/
https://ncbi.nlm.nih.gov/pubmed/26313416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2015.1081566
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi